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A novel RFX6 homozygous missense mutation was identified in an infant with Mitchell-Riley syndrome. The most common
features of Mitchell-Riley syndrome were present, including severe neonatal diabetes associated with annular pancreas, intestinal
malrotation, gallbladder agenesis, cholestatic disease, chronic diarrhea, and severe intrauterine growth restriction. Perijejunal tissue
similar to pancreatic tissue was found in the submucosa, a finding that has not been previously reported in this syndrome. This
case associating RFX6 mutation with structural and functional pancreatic abnormalities reinforces the RFX6 gene role in pancreas
development and 𝛽-cell function, adding information to the existent mutation databases.
1. Introduction
In the rare Mitchell-Riley syndrome (OMIM #601346)
recently described, severe neonatal diabetes associated with
hypoplastic or annular pancreas, duodenal or jejunal atre-
sia, intestinal malrotation, gallbladder hypoplasia or agen-
esis, and cholestatic disease are the most common features
described [1, 2].
Homozygosity mapping has identified chromosomal
regions linked to Mitchell-Riley syndrome, in which the
regulatory factor X 6 (RFX6) gene was identified [3]. The
RFX family has 7 members of transcription factors with a
highly conservedDNA-binding domain.TheRFX3 andRFX6
members are important for 𝛽-cell formation and function
[4]. Mutations in RFX6 are assumed to be the cause of
neonatal diabetes in this syndrome, through the production
of a defective RFX6 protein [2–5]. Recently, Concepcion et al.
[2] reviewed the RFX6 mutations found in the eight patients
(seven probands) reported to date with neonatal diabetes and
multiple congenital digestive tract anomalies.
Herein, a novel RFX6 mutation is reported in an infant
with Mitchell-Riley syndrome.
2. Case Report
We report a girl, the second child of first-cousin Gipsy
parents. Before the proband, the 28-year-old mother had 3
spontaneous abortions in the first trimester and a child with
isolated congenital anorectal malformation.
The ultrasound scanning at 33 weeks of gestation revealed
intrauterine growth restriction without umbilical artery flow
changes, and a “double bubble” suggestive of duodenal atresia.
A normal 46, XX karyotype was observed in fetal cells
and the fetal echocardiogram was normal. She was born
at 35 weeks of gestation by spontaneous vaginal delivery.
At birth she appeared malnourished with weight, length,
and head circumference below the 3rd centile, respectively,
1370 g, 44 cm, and 29.5 cm. No dysmorphic features were
noted, except for anteriorly placed anus. The first hours after
birth were complicated with anemia (hemoglobin 9.8 g/dL),
oliguria, and metabolic acidosis, improving with volume
expansion and red blood cell transfusion. On day 2 hyper-
glycemia (415mg/dL) occurred, requiring continuous insulin
infusion along with parenteral nutrition with glucose rates
around 5-6mg/Kg/min. On day 3 the blood insulin level
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was 0.12 𝜇UI/mL and C peptide was <0.1 ng/mL during
an episode of hyperglycemia (312mg/dL). Glutamic acid
decarboxylase (GADA), islet cell (ICA), and islet antigen 2
(IA-2) autoantibodies were negative.
On day 4 laparotomy confirmed duodenal atresia (type
II) that was associated with annular pancreas, malrotation,
and gallbladder agenesis. Perijejunal tissue in the submucosa
was foundwithmacroscopic appearance of ectopic pancreatic
tissue; instability of the patient during surgery precluded
the biopsy of the tissue for histological confirmation. Duo-
denoduodenostomy and Ladd’s procedures were performed.
Preoperative analyses showed bilirubin and liver enzymes
within normal values. FromD6 cholestasis appeared and pro-
gressively worsened reaching levels of conjugated bilirubin
of 3.07mg/dL, gamma-glutamyl transpeptidase of 458 IU/L,
with relatively normal alkaline phosphatase 94–149 IU/L
and transaminases. Subsequently, cholestasis progressively
improved and normalization occurred by two months of
age without any specific treatment. On day 7 the abdominal
ultrasound showed biliary duct dilation with 3mm greater
axis, slightly tortuous, with diminished caliber of intrahepatic
right and left biliary ducts; the cephalic region of pancreaswas
disproportionately larger than the body with unidentifiable
tail.
Enteral nutrition was initiated on day 9; however diar-
rhea developed when enteral volume of breast milk and/or
extensively hydrolyzed formula was increased. Exocrine pan-
creatic supplementation has been unsuccessful and even with
free amino acids formula she maintained diarrhea, limiting
enteral feeding progression.
Currently she is seven months old and still has malab-
sorption with failure to thrive (weight 4865 g). Insulin was
administered by continuous infusion up to age of fivemonths
and subsequently by insulin pump. Complementary feeding
was initiated at the age of sixmonths, but she is still dependent
on free amino acids formula and parenteral nutrition which
provides approximately 60% of daily energy.
The proband and her parents underwent genetic analysis
of RFX6 gene. Genomic DNA was extracted from peripheral
leukocytes using standard procedures and the coding region
and intron/exon boundaries of the RFX6 gene were amplified
by PCR (primers available on request). Amplicons were
sequenced using the Big Dye Terminator Cycler Sequencing
Kit v3.1 (Applied Biosystems, Warrington, UK) according to
manufacturer’s instructions and reactions were analysed on
an ABI 3730 Capillary sequencer (Applied Biosystems, War-
rington, UK). Sequences were compared with the reference
sequences (NM 173560.3) using Mutation Surveyor v3.24
software (SoftGenetics, State College, PA). A homozygous
missense mutation was identified on exon 4, c.541C>T,
p.R181W in the proband. Both parents are heterozygous.
3. Discussion
In permanent neonatal diabetes mellitus a genetic cause can
be identified in around half the cases and the altered gene
expression usually affects pancreas development, 𝛽-cell mass,
or 𝛽-cell function [4].Themost frequent gene with identified
mutations is KCNJ11 and to a lesser extent GCK, ABCC8,
and HNF1𝛽. Most patients with neonatal diabetes do not
have other congenital abnormalities [6]. The association of
the particular phenotype of Martinez-Frias syndrome with a
mutation on the RFX6 gene and neonatal diabetes has been
called Mitchell-Riley syndrome, and it was suggested that
both syndromes represent a symptom continuumor an RFX6
malformation complex [7].
The most common features described in Mitchell-Riley
syndrome were present in the reported case, including severe
neonatal diabetes associatedwith annular pancreas, intestinal
malrotation, gallbladder agenesis, abnormal biliary tract,
cholestatic disease, chronic diarrhea, intrauterine growth
restriction, and consanguinity [1, 2, 4]. Some less common
features have also been reported [1, 2]. Similarly to our case,
anemia at birth requiring prompt red blood cell transfusion
has been previously described [1, 5, 8]. Precocious anemia
may have been due to fetomaternal transfusion, but this
was not investigated. A novel feature found in our case
was the perijejunal tissue similar to pancreatic tissue in the
submucosa. Unfortunately, instability of the patient during
surgery precluded the biopsy for histological confirmation.
Two theories have been suggested for heterotopic pancreatic
tissue: during embryological development buds of embryonic
tissue penetrate into the wall of the growing gut separating
from the main pancreas; alternatively, inappropriate expres-
sion of pluripotent embryonic mesenchymal tissue of the
gastrointestinal tract may lead to pancreatic metaplasia [9–
11].
All the seven probands previously reportedwithMitchell-
Riley syndrome presented RFX6 mutations [2]. To the best
of our knowledge this is the eighth proband with Mitchell-
Riley syndrome and RFX6 mutation, in whom the novel
p.R181W mutation was found. The arginine residue at codon
181, located in the DNA binding domain, is highly conserved
across species and this change affects protein function. This
mutation was not listed before and is likely pathogenic.
A different mutation at the same residue has already been
reported in patients with Mitchell-Riley syndrome (p.R181Q)
[4].
In Mitchell-Riley syndrome accurate genetic counselling
is inseparable from molecular diagnosis, offering better
reproductive options and prenatal diagnosis to the couple and
genetic counselling to family members at risk.
The present report reinforces that severe neonatal dia-
betes associated with RFX6 gene mutation constitutes a
distinct phenotype presently described as Mitchell-Riley
syndrome. This strongly suggests that RFX6 has a specific
role in pancreas development and 𝛽-cell function. The novel
mutation herein described may contribute to clarifying the
reported genetic heterogeneity and adds valuable informa-
tion to the existent mutation databases.
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